Oncotelic Therapeutics, Inc. made headlines recently with its presentation at the 22nd Drug Discovery Strategic Summit held on October 21-22, 2026. The event took place at the Westin San Francisco Airport, where Chief Business Officer Saran Saund discussed the company's advancements in liver cancer research.
The presentation, titled "Partitioning 29 Million PubMed Abstracts by Disease Turns a Literature Review into a Discovery. A Four-Gene mTOR Signature Defining a Candidate Hepatocellular Carcinoma Population," showcased Oncotelic's innovative approach to drug discovery. This framework, known as Partitioned Literature Aggregation (PLA), integrates literature analysis with gene-expression and survival analyses to identify significant genetic signatures associated with patient outcomes.
Oncotelic's research focuses on a four-gene mTOR-related signature that could potentially enhance the understanding of hepatocellular carcinoma, a common type of liver cancer. The presentation also outlined the company's plans for expanding the PLA framework through the use of autonomous AI agents, targeting a vast database of 100 billion protein-related vectors to support drug discovery across various disease areas.
This presentation is significant not only for Oncotelic but also for the pharmaceutical preparations industry as a whole. The integration of AI in drug discovery could lead to more efficient and targeted therapies, potentially transforming how research is conducted in the field.
Details about the summit and the presentation can be found through the provided hyperlink to the event's details.
The filing does not specify what actions will follow this presentation, leaving the industry and stakeholders eager for further developments from Oncotelic Therapeutics.